Thị trường máy phân tích huyết học - Tăng trưởng, Xu hướng, Tác động và Dự báo của COVID-19 (2023 - 2028)

The rising COVID-19 cases and the lockdown and inhibitions on the intercountry transport were found to have an impact on the supply chain of the systems. Initially, many manufacturers have thus stopped production due to the lack of labor that is found impacting the segment growth. However, the increasing focus on hematology parameters for the assessment of COVID-19 has increased the demand for hematology analyzers. In the case of the COVID-19 pandemic, 3-part hematology analyzers were found to be cost-effective as the samples required to test are huge. Furthermore, demand may surge post the COVID-19 pandemic also.

Moreover, A 3-part differential cell counter uses Coulter's Principle to find the size and volume of the cell. The sample is lysed and dissolved into an electrolyte solution in a container, which holds a smaller container. 3-part hematology analyzer systems are ideally suited for physician office laboratories, clinics, and small hospitals that perform moderately complex testing. There is increased interest in 5-part hematology analyzers. However, 3-part hematology analyzers are more cost-effective for routine hematological tests. Furthermore, with advancements in technology and availability of these instruments across the world coupled with affordability, the market is projected to have notable growth.

In March 2019, Transasia Bio-Medicals Ltd launched the 3-Part Differential (3PD) fully automated hematology analyzers, reagents, and controls in India manufactured by Erba Lachema, a fully owned European subsidiary of Transasia. Later in September 2019, Transasia Bio-Medicals Ltd. announced that it has successfully sold over 1,000 units of its Erba Hematology range of analyzers in India.

In April 2019, Prestige Diagnostics launched its NEW Hematron 3 PLUS Hematology Analyzer, globally. It is a 3-part differential hematology analyzer capable of performing 18 parameters with 3 histograms.

Furthermore, the clinical laboratories as end users are the centers where hematology tests are performed. Usually, they have high-quality equipment, and the results obtained from them are accurate. The automation of laboratories has increased the equipment costs in this segment. However, analyzers are not frequently replaced in these laboratories. The clinical testing laboratories perform various tests on whole blood, serum, urine, cerebrospinal fluids, and other body fluids. Furthermore, convenience and accurate results are the two major reasons driving the growth of the segment over the forecast period.

The United States is one of the most COVID-affected countries across the world. Due to the outbreak of COVID-19, the market is expected to face a slight setback owing to the delay in diagnosis, drug shortages, and others. However The outbreak of COVID-19 is expected to impact the market, as individuals with blood conditions, such as hemophilia, should take extra precautions to minimize the risk of contracting COVID-19, as this group of the population is more prone to infectious diseases.

The market for hematology analyzers in the North American region is growing at a steady pace. This can be attributed to the increasing burden of blood disorders and the growth in the adoption of hematology analyzers by the diagnostic industry. For instance, anemia, which is a common disorder, affects more than three million Americans, particularly women of ‘childbearing age.

According to the World Federation of Hemophilia 2018 report, in 2018, there were about 17,757 people diagnosed with hemophilia in the United States. Furthermore, in 2019, the number of people with hemophilia in the United States increased to about 20,000 individuals, as per NHF (National Health Federation). According to the Leukemia and Lymphoma Society, every three minutes, a person in the United States is diagnosed with blood cancer. About 176,200 people in the United States were diagnosed with leukemia, lymphoma, or myeloma, in 2019.

Many market players are present in the country and are continuously focusing on the development and introduction of novel products. In December 2019, Beckman Coulter subsidiary of Danaher Corporation had launched a new DxH 690T hematology analyzer, designed to help laboratories streamline workflow and maximize uptime. Similarly, in April 2019, Ortho Clinical Diagnostics, in collaboration with Diazyme Laboratories Inc., launched its D-Dimer assay, the latest offering in Ortho’s MicroTip Partnership Assay (MPA) program for coagulation testing in the United States.

Moreover, In the United States, there are a number of associations helping both clinicians and scientists across the world who are working to conquer such blood diseases. Furthermore, many centers in the state are international leaders in the diagnosis and treatment of blood diseases and collaborate in many research projects to improve diagnosis and treatment options for blood diseases. These factors drive the demand for hematology analyzers in the North American region.